MedPath

Liaoning Chengda Biotechnology Co.,Ltd.

Ownership
-
Established
2002-06-17
Employees
1.7K
Market Cap
-
Website
https://www.cdbio.cn
Introduction

The company was founded in June 2002. With the corporate mission of “providing high-quality biological products and caring for human life and health”, the company always adheres to the core values of “honesty, kindness and harmony, and responsibility and cooperation”, adheres to the corporate philosophy of “facing life, only responsibility”, and is committed to becoming an excellent international biopharmaceutical company. The company's main business is R&D, production and sales of human vaccines. The main products are human rabies vaccine and human encephalitis B vaccine. Corporate glory: high-tech enterprise, Liaoning Science and Technology Award, independent innovation of famous products, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

5

NMPA:5

Drug Approvals

Japanese Encephalitis Vaccine (Vero cell), Inactivated ,Freeze-dried

Product Name
冻干乙型脑炎灭活疫苗(Vero细胞)
Approval Number
国药准字S20083042
Approval Date
Dec 27, 2022
NMPA

Japanese Encephalitis Vaccine (Vero cell),Inactivated

Product Name
乙型脑炎灭活疫苗(Vero细胞)
Approval Number
国药准字S20083041
Approval Date
Dec 27, 2022
NMPA

Japanese Encephalitis Vaccine(Vero Cell), Inactivated

Product Name
乙型脑炎灭活疫苗(Vero细胞)
Approval Number
国药准字S20202001
Approval Date
Dec 27, 2022
NMPA

Rabies Vaccine (Vero cell) for Human Use, Freeze-dried

Product Name
冻干人用狂犬病疫苗(Vero细胞)
Approval Number
国药准字S20043090
Approval Date
Jun 24, 2020
NMPA

Rabies Vaccine (Vero Cell) for Human Use

Product Name
人用狂犬病疫苗(Vero细胞)
Approval Number
国药准字S20043089
Approval Date
Jun 24, 2020
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.